Press Releases

Global Market for Cancer Immunotherapies to Reach $67.9 Billion in 2018; North America Moving At 15% CAGR

April 25, 2014

Wellesley, Mass., April 25, 2014 – BCC Research ( reveals in its new report,CANCER IMMUNOLOGY AND ONCOLYTIC VIROLOGY: TECHNOLOGIES AND GLOBAL MARKETS the global market for cancer immunotherapies is expected to grow to nearly $67.9 billion by 2018, with a five-year compound annual growth rate (CAGR) of 14.7%. North American market, the fastest growing regional segment overall, is growing at a tremendous 15% CAGR.

With rising instances of cancer and improving access to healthcare, North America is far and away the largest segment in the overall market for cancer immunotherapies and is expected to grow to nearly $30.1 billion by 2018.

However, Japan, which was valued at $3.8 billion in 2013, is expected to nearly double in size by 2018 to reach nearly $7.3 billion, registering a 14.1% CAGR.

“There is an increasing need for new and innovative drugs,” says BCC Research pharmaceutical analyst Valerie Kellogg. “However, in the last few years, the technology has developed to the point where autologous drugs and gene transfers can be used by researchers to finally bring new treatments to clinic. This young industry is experiencing tremendous growth.”

CANCER IMMUNOLOGY AND ONCOLYTIC VIROLOGY: TECHNOLOGIES AND GLOBAL MARKETS provides an overview of the current and potential global market for cancer immunotherapy and virology. It presents analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018. The study also includes comprehensive information on a number of the most common cancers, highlighting global incidence and prevalence. In addition, the report identifies the need for more effective drugs for treatment of these diseases.

To Contact us, click here  

Source: BCC Research

This report is intended for the pharmaceutical and biotechnology industries, as well as clinics, hospitals, and research institutes. 

Editors and reporters who wish to speak with the analyst, should contact Steven Cumming at

Cancer Immunology and Oncolytic Virology: Technologies and Global Markets( PHM129A )
Publish Date:     

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.